Liege, Belgium, 24 June 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, is pleased to announce today the successful renegotiation of the earnouts linked to two products of its Complex Therapeutic portfolio: the Zoreline® implant and the Myring® contraceptive hormonal ring.
Share it
Latest news
Mithra reaches milestone in estetrol skin study
8 April 2024
Mithra updates on its ongoing monetization process
28 March 2024